The Pharmasyntez Group has secured an impressive third place among Russia's best pharmaceutical manufacturers in Forbes' 2025 rating. This achievement underscores the company's outstanding professionalism and innovative approach, which have been developed over years of devoted work creating high-quality and potent medications.

Specializing in a broad range of pharmaceuticals, Pharmasyntez covers multiple therapeutic areas including oncology, infectious diseases, and endocrinology. The company maintains its position at the forefront of pharmaceutical science through continuous investment in research and development, delivering cutting-edge solutions that improve patients' quality of life.

By combining advanced technologies, highly skilled professionals, and efficient management, the Pharmasyntez Group has established itself as a market leader in Russia's pharmaceutical industry. Its inclusion in the Forbes ranking serves as recognition of the company's accomplishments and confirms its standing as a trusted partner for healthcare providers, patients, and business collaborators alike.